Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

154.58
-0.3500-0.23%
Post-market: 153.90-0.6801-0.44%19:57 EDT
Volume:8.64M
Turnover:1.33B
Market Cap:371.93B
PE:17.20
High:154.90
Open:154.32
Low:152.45
Close:154.93
Loading ...

Johnson & Johnson - Tremfya Phase 3B Study Achieves Primary and Secondary Endpoints

THOMSON REUTERS
·
04 Apr

Tremfya® (Guselkumab) Is the First and Only Il-23 Inhibitor to Significantly Reduce Both the Signs and Symptoms and the Progression of Structural Damage in Adults Living With Active Psoriatic Arthritis

THOMSON REUTERS
·
04 Apr

Johnson & Johnson - Tremfya Safety Profile Consistent With No New Safety Signals

THOMSON REUTERS
·
04 Apr

Johnson & Johnson - Tremfya Shows Less Structural Damage Progression at Week 24

THOMSON REUTERS
·
04 Apr

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis

PR Newswire
·
04 Apr

ADVISORY-Dated alerts on J&J referring to Red River Talc bankruptcy withdrawn

Reuters
·
04 Apr

Johnson & Johnson Faces Bankruptcy Plan Rejection

TIPRANKS
·
04 Apr

Johnson & Johnson - to Reverse $7 Billion From Bankruptcy Reserve - SEC Filing

THOMSON REUTERS
·
04 Apr

FDA delay on Novavax vaccine approval could be bellwether for vaccine sector: BofAS

Yahoo Finance
·
04 Apr

Pharma Stocks Aren't in the Clear, Despite Tariff Exemption-Heard on the Street -- WSJ

Dow Jones
·
03 Apr

Pharma Stocks Survive Market Rout on Tariff Exemption, but Uncertainty Continues

Reuters
·
03 Apr

JNJ vs. PFE: Which Drug Giant is a Better Buy Now?

Zacks
·
03 Apr

BUZZ-US drugmakers rise on reprieve from Trump tariffs

Reuters
·
03 Apr

Shares of US Drugmakers Rise After Tariff Exemption

THOMSON REUTERS
·
03 Apr

Shares of Abbvie up 2.5%, Johnson & Johnson up 2.5%, Merck up 1.9%, Amgen up 2.2%

THOMSON REUTERS
·
03 Apr

Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.

Motley Fool
·
03 Apr

Big Pharma Avoids Worst-Case Tariff Scenario -- WSJ

Dow Jones
·
03 Apr

Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider

Zacks
·
03 Apr

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

GlobeNewswire
·
03 Apr

Johnson & Johnson Price Target Maintained With a $181.00/Share by RBC Capital

Dow Jones
·
03 Apr